NEW YORK, NY / ACCESSWIRE / December 17, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/adamas-pharmaceuticals-inc-loss-submission-form?prid=4935&wire=1
Lead Plaintiff Deadline: February 10, 2020
Class Period: August 8, 2017 to September 30, 2019

Allegations against ADMS include that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Sealed Air Corporation (NYSE:SEE)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sealed-air-corporation-loss-submission-form?prid=4935&wire=1
Lead Plaintiff Deadline: December 31, 2019
Class Period: November 5, 2014 to August 6, 2018

Allegations against SEE include that: (a) Sealed Air had hired its auditor, E&Y, pursuant to a conflicted and improper process and in order to help facilitate defendants' efforts to engage in accounting fraud; (b) Sealed Air's deduction of $1.49 billion in connection with the Settlement was indefensible and done for the improper purpose of artificially inflating the Company's financial results; (c) Sealed Air had artificially inflated its earnings, cash flows, and operating income during the Class Period; (d) as a result of the above, Sealed Air's Class Period financial statements were materially false and misleading and not prepared in conformance with GAAP; and (e) as a result of the above, Sealed Air's statements regarding its financial results, business, and prospects were materially misleading.

Exelon Corporation (NYSE:EXC)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/exelon-corporation-loss-submission-form?prid=4935&wire=1
Lead Plaintiff Deadline: February 14, 2020
Class Period: February 9, 2019 to November 1, 2019

Allegations against EXC include that: (i) Exelon and/or its employees were engaged in unlawful lobbying activities; (ii) the foregoing increased the risk of a criminal investigation into Exelon; (iii) Exelon subsidiary Commonwealth Edison's revenues were in part the product of unlawful conduct and thus unsustainable; and (iv) that, as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 570620

BALA CYNWYD, PA / ACCESSWIRE / December 17, 2019 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.

ARQULE, INC. (NasdaqGS:ARQL)

Under the terms of the agreement, ArQule shareholders will receive only $20.00 for each share of ArQule common stock owned. The investigation concerns whether the ArQule Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Merck is underpaying for the Company. For example, ArQule's lead new drug candidate under development, called ARQ 531, is a potential treatment of B-cell malignancies including relapsed or refractory chronic lymphocytic leukemia. Merck's President commented, "ArQule's focus on precision medicine has yielded multiple clinical-stage oral kinase inhibitors that have novel and important properties, …. This acquisition strengthens Merck's pipeline with the addition of these strategic assets."

Additional information can be found at http://www.brodskysmith.com/cases/arqule-inc-nasdaqgs-arql/, or call 877-534-2590. No cost or obligation to you.

AUDENTES THERAPEUTICS, INC. (NasdaqGS:BOLD)

Under the terms of the agreement, Audentes shareholders will receive only $60.00 for each share of Audentes common stock owned. The investigation concerns whether the Audentes Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Astellas Pharma, Inc.is underpaying for the Company. The transaction may undervalue the Company. For example, the merger will provide Astellas with Audentes robust pipeline, including its lead program AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).

Additional information can be found at http://www.brodskysmith.com/cases/audentes-therapeutics-inc-nasdaqgs-bold/, or call 877-534-2590. No cost or obligation to you.

KEMET CORPORATION (NYSE:KEM)

Under the terms of the agreement, KEMET shareholders will receive only $27.20 for each share of KEMET common stock owned. The investigation concerns whether the KEMET Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Yageo Corporation is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many KEMET shareholders. For example, an analyst following the stock has set a price target of $29.00.

Additional information can be found at http://www.brodskysmith.com/cases/kemet-corporation-nyse-kem/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 570426

BALA CYNWYD, PA / ACCESSWRIE / December 17, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Tallgrass Energy LP ("Tallgrass Energy" or "the Company") (NYSE – TGE) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by Blackstone Infrastructure Partners ("Blackstone"). Under the terms of the agreement, Tallgrass Energy shareholders will receive only $22.45 for each share of Tallgrass Energy common shares owned.

The investigation concerns whether the Tallgrass Energy Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Blackstone is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many Tallgrass Energy shareholders. For example, the deal price is well below the 52-week high of $25.96.

If you own shares of Tallgrass Energy and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://www.brodskysmith.com/cases/tallgrass-energy-lp-nyse-tge/, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Law office of Brodsky & Smith, LLC

ReleaseID: 570595

BALA CYNWYD, PA / ACCESSWIRE / December 17, 2019 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.

INSTRUCTURE, INC. (NYSE:INST)

Under the terms of the agreement, Instructure shareholders will receive only $47.60 for each share of Instructure common stock owned. The investigation concerns whether the Instructure Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Thoma Bravo is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many Instructure shareholders. For example, the stock was trading over $53 a share in November 2019 and at least one analyst following the Company has set a price target of $56.00

Additional information can be found at http://www.brodskysmith.com/cases/instructure-inc-nyseinst/, or call 877-534-2590. No cost or obligation to you.

TIFFANY & CO. (NYSE:TIF)

Under the terms of the agreement, Tiffany shareholders will receive only $135.00 for each share of Tiffany common stock owned. The investigation concerns whether the Tiffany Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether LVMH is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many Tiffany shareholders. For example, at least one analyst following the Company has set a price target of $160.00.

Additional information can be found at http://www.brodskysmith.com/cases/tiffany-co-nyse-tif/, or call 877-534-2590. No cost or obligation to you.

TD AMERITRADE (Nasdaq:AMTD)

Under the terms of the agreement, TD Ameritrade shareholders will receive only 1.0837 shares of Charles Schwab stock for each share of TD Ameritrade common stock owned. This exchange ratio implied a deal price of $52.23 as of the last day of trading before the announcement. The investigation concerns whether the TD Ameritrade Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Charles Schwab is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many TD Ameritrade shareholders. For example, at least one analyst following the Company has set a price target of $60.00. Additionally, the implied deal price is well-below the 52-week high of $57.88.

Additional information can be found at http://www.brodskysmith.com/cases/td-ameritrade-holding-corporation-nasdaqgs-amtd/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 570418

LOS ANGELES, CA / ACCESSWIRE / December 17, 2019 / The Schall Law Firm,a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Yunji Inc. ("Yunji" or "the Company") (NASDAQ:YJ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission."

Investors who purchased the Company's securities pursuant and/or traceable to the Company's Registration Statement issued in connection with its May 2019 initial public stock offering (the "IPO" or "Offering"), are encouraged to contact the firm before January 13, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Yunji shifted sales to its marketplace, a restructuring likely to disrupt the Company's relationships with suppliers. The change was also likely to have a negative impact on financial results. Based on these facts, the Company's public statements were false and materially misleading throughout the IPO period. When the market learned the truth about Yunji, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570609

NEW YORK, NY / ACCESSWIRE / December 17, 2019 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a motion to serve as lead plaintiff in a securities class action filed on behalf of investors that purchased or acquired the securities of Merit Medical Systems, Inc. ("Merit" or the "Company") (NASDAQ:MMSI) between February 26, 2019 and October 30, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Central District of California alleges violations of the Securities Exchange Act of 1934.

If you purchased Merit securities, and/or would like to discuss your legal rights and options please visit Merit Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

The complaint alleges that during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information concerning Merit's business and prospects. Specifically, defendants failed to disclose that: (a) the integrations of Cianna and Vascular Insights, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during fiscal 2019; and (c) in light of the foregoing, the Company's reported financial guidance for fiscal 2019 and 2020 was made without a reasonable basis.

On July 25, 2019, following the Company's second quarter 2019 financial results the Company held a conference call for analyst's and investors to discuss the results. On that call Defendants admitted that the miss and guidance reduction were in part due to the fact that ClariVein had zero orders for the first half of the year due to pipeline filling prior to the acquisition.

Following these disclosures the Company's stock price fell more than 25% from a close of $54.84 per share on July 25, 2019, to a close of $41.00 per share on July 26, 2019, on volume of more than 6.2 million shares.

Then, on October 30 2019, after the market closed, the Company issued a press release announcing the Company's third quarter 2019 financial results. The Company disclosed significant operational issues in all aspects of Merit's business. Defendants admitted that they were months behind in their integration of Cianna and Vascular Insights, their integration of R&D facilities was too expensive and had necessitated a 2% to 5% reduction in headcount, and that they had to take a material revenue recognition adjustment in the quarter.

Following this disclosure, Merit's stock price declined more than 29%, from a close of $29.11 per share on October 30, 2019, to a close of $20.66 per share on October 31, 2019.

If you purchased Merit securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/meritmedicalsystems-mmsi-shareholder-investigation-stock-fraud-lawsuit-169/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

If you wish to serve as lead plaintiff, you must move the Court no later than February 3, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com

SOURCE: Bernstein Liebhard LLP

ReleaseID: 569182

NEW YORK, NY / ACCESSWIRE / December 17, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Energy Transfer LP (NYSE:ET)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/energy-transfer-lp-loss-submission-form?prid=4934&wire=1
Lead Plaintiff Deadline: January 20, 2020
Class Period: February 25, 2017 to November 11, 2019

Allegations against ET include that: (i) Energy Transfer's permits to conduct the Mariner East pipeline project in Pennsylvania were secured via bribery and/or other improper conduct; (ii) the foregoing misconduct increased the risk that the Partnership and/or certain of its employees would be subject to government and/or regulatory action, thereby depreciating the Partnership's unit value; and (iii) as a result, the Partnership's public statements were materially false and misleading at all relevant times.

Prudential Financial, Inc. (NYSE:PRU)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/prudential-financial-inc-loss-submission-form?prid=4934&wire=1
Lead Plaintiff Deadline: January 27, 2020
Class Period: February 15, 2019 to August 2, 2019

Allegations against PRU include that: (a) the Company's reserve assumptions failed to account for adversely developing mortality experience in the Individual Life business segment; (b) the Company was not over-reserved, but instead, its reported reserves, particularly for the Individual Life business segment, were insufficient to satisfy its future policy benefits liabilities; and (c) the Company had materially understated its liabilities and overstated net income as a result of flawed assumptions in calculating mortality experience.

Fiat Chrysler Automobiles N.V. (NYSE:FCAU)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fiat-chrysler-automobiles-n-v-loss-submission-form?prid=4934&wire=1
Lead Plaintiff Deadline: January 31, 2020
Class Period: February 26, 2016 to November 20, 2019

Allegations against FCAU include that: (1) the Company employed a bribery scheme to obtain favorable terms in its collective bargaining agreement with United Automobile, Aerospace and Agricultural Implement Workers of America; (2) high-ranking Fiat officials were aware of and authorized the scheme; and (3) as a result, Defendants' statements about Fiat's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 570603

LOS ANGELES, CA / ACCESSWIRE / December 17, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Net 1 UEPS Technologies, Inc. ("UEPS" or "the Company") (NASDAQ:UEPS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between September 12, 2018 and November 8, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before February 3, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. UEPS failed to maintain effective controls on financial reporting. The Company misclassified its investment in Cell C Proprietary Limited. The Company's financial statements for fiscal year 2018 overstated its income. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about UEPS, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570602

LOS ANGELES, CA / ACCESSWIRE / December 17, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Exelon Corporation ("Exelon" or "the Company") (NASDAQ:EXC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 9, 2019 and November 1, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 14, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Exelon and its employees engaged in improper lobbying of government officials. These actions increased the likelihood of a criminal investigation of the Company. Exelon subsidiary Commonwealth Edison gained revenues as a result of the improper conduct which would be unsustainable in the future. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Exelon, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570601

LOS ANGELES, CA / ACCESSWIRE / December 17, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Live Nation Entertainment, Inc. ("Live Nation" or "the Company") (NYSE:LYV) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The Wall Street Journal reported on December 13, 2019, that the DOJ is preparing to take legal action against Live Nation. The legal action is based on allegations that the Company strong-armed venues into using its Ticketmaster subsidiary. This would be a violation of the Company's 2010 settlement as part of its merger with Ticketmaster. Based on this news, shares of Live Nation fell by 7.3% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570600